Sabba Stephen L Insider Trading Activity

Average Profitability
53.3%
Insider Buys Quantity
3
Insider Buys Sum
$109,230.00
Insider Sells Quantity
6
Insider Sells Sum
$2.19M

Insider Activity of Sabba Stephen L

According to the SEC Form 4 filings, Sabba Stephen L, being in a position of

  1. director at Ligand Pharmaceuticals Incorporated,
    оver the last 12 months, has bought 0 shares, and sold 5179 shares for $1.16M,
    over all time since 2011-11-10, has bought 4000 shares for $109,230, and sold 20527 shares for $3.35M.

Biography of Sabba Stephen L

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$1,162,5543100

Comparison of Insiders on Amount of Buys and Sells

2026-06-16SaleLigand Pharmaceuticals Incorporated
LGND
director
2,145
0.0107%
$254.00$544,830+16.14%
2026-03-23SaleLigand Pharmaceuticals Incorporated
LGND
director
1,000
0.0052%
$207.87$207,873+43.05%
2026-03-03SaleLigand Pharmaceuticals Incorporated
LGND
director
2,034
0.0103%
$201.50$409,851+39.14%
2024-03-05SaleLigand Pharmaceuticals Incorporated
LGND
director
1,893
0.0108%
$74.30$140,650+39.14%
2023-05-10SaleLigand Pharmaceuticals Incorporated
LGND
director
6,408
0.0373%
$77.13$494,225-9.31%
2018-09-04SaleLigand Pharmaceuticals Incorporated
LGND
director
5,000
0.0233%
$255.05$1.28M-52.36%
2018-03-12SaleLigand Pharmaceuticals Incorporated
LGND
director
622
0.0029%
$180.73$112,414-7.46%
2017-12-20SaleLigand Pharmaceuticals Incorporated
LGND
director
925
0.0044%
$137.25$126,956+25.62%
2014-10-09PurchaseLigand Pharmaceuticals Incorporated
LGND
director
2,000
0.01%
$43.12$86,230+87.4%
2014-02-27SaleLigand Pharmaceuticals Incorporated
LGND
director
500
0.0025%
$72.25$36,125-22.56%
2011-11-14PurchaseLigand Pharmaceuticals Incorporated
LGND
director
1,000
0.0051%
$11.50$11,500+32.78%
2011-11-10PurchaseLigand Pharmaceuticals Incorporated
LGND
director
1,000
0.0054%
$11.50$11,500+39.65%
Total: 12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.